- Home
- TRNO vs PCVX Comparison
TRNO vs PCVX Comparison
Compare TRNO & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TRNO | PCVX |
|---|---|---|
| Founded | 2009 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8B | 6.1B |
| IPO Year | 2009 | 2020 |
Fundamental Metrics
Financial Performance| Metric | TRNO | PCVX |
|---|---|---|
| Price | $62.75 | $57.45 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 7 |
| Target Price | $67.83 | ★ $98.33 |
| AVG Volume (30 Days) | 585.0K | ★ 1.1M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 3.29% | N/A |
| EPS Growth | ★ 103.65 | N/A |
| EPS | ★ 3.91 | N/A |
| Revenue | ★ $476,383,000.00 | N/A |
| Revenue This Year | $7.62 | N/A |
| Revenue Next Year | $8.75 | N/A |
| P/E Ratio | $16.15 | ★ N/A |
| Revenue Growth | ★ 24.51 | N/A |
| 52 Week Low | $53.00 | $28.09 |
| 52 Week High | $67.70 | $76.61 |
Technical Indicators
Market Signals| Indicator | TRNO | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 40.85 | 51.28 |
| Support Level | $59.00 | $42.30 |
| Resistance Level | $62.75 | $65.00 |
| Average True Range (ATR) | 1.20 | 3.01 |
| MACD | -0.53 | -0.60 |
| Stochastic Oscillator | 32.23 | 21.13 |
Price Performance
Historical ComparisonAbout TRNO Terreno Realty Corporation
Terreno Realty Corp is a real estate investment trust engaged in acquiring, owning, and operating industrial real estate in six coastal U.S. markets: Los Angeles, Northern New Jersey/New York City, San Francisco Bay Area, Seattle, Miami, and Washington, D.C. The company invests in several types of industrial real estate, including warehouse/distribution, flex (including light industrial and research and development), transshipment, and improved land.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.